Malaria: New research promises to ease access to ASAQ and ASMQ treatment
Malaria: New research promises to ease access to ASAQ and ASMQ treatment
Access to effective treatment is central in the fight against malaria. The recently published PREGACT study has shown that artemisinin-based combination therapies are effective in pregnant women with malaria in Africa, without the safety concerns of other treatment types. Another success for malaria treatment comes with the World Health Organization’s announcement that the fixed-dose combination of artesunate+mefloquine (ASMQ) shelf-life has been extended from two to three years, which will greatly help with storage and distribution.
Malaria: New research promises to ease access to ASAQ and ASMQ treatment
Call for papers for PLOS WorldLeish-6 Collection
Call for papers for PLOS WorldLeish-6 Collection
Dr Jorge Alvar, Head of Visceral Leishmaniasis, DNDi, and Dr Javier Moreno, Director of WHO Collaborating Center for Leishmaniasis, announce a call for papers on Leishmaniasis for the PLOS WorldLeish-6 Collection. See the PLOS article, calling for papers for the PLOS WorldLeish 6 Collection, as it appeared on the PLOS Blog.
Call for papers for PLOS WorldLeish-6 Collection
Hepatitis C: Current barriers to treat patients and DNDi’s R&D strategy to address urgent needs
Hepatitis C: Current barriers to treat patients and DNDi’s R&D strategy to address urgent needs
DNDi, Pharco, and the Ministry of Health Malaysia announced today at the International Liver Congress in Barcelona, Spain, that they signed agreements to test an affordable hepatitis C regimen in Malaysia and Thailand. The treatment, a potentially pan-genotypic combination of ravidasvir and sofosbuvir, will be tested in Malaysia and Thailand with a target price of under $300. DNDi also released its hepatitis C R&D Strategy as well as infographics to explain why there are so many neglected hepatitis C patients.
Hepatitis C: Current barriers to treat patients and DNDi’s R&D strategy to address urgent needs
GHIT invests in GeneDesign and DNDi partnership to develop a better treatment for cutaneous leishmaniasis
GHIT invests in GeneDesign and DNDi partnership to develop a better treatment for cutaneous leishmaniasis
GHIT awarded US$687,715 to a partnership between GeneDesign, a Japan-based biotech, and DNDi to develop a better treatment for cutaneous leishmaniasis.
GHIT invests in GeneDesign and DNDi partnership to develop a better treatment for cutaneous leishmaniasis
See all news

Scientific Articles

See all scientific articles

Events

  • Dundee Drug Discovery Unit: Celebrating 10 years May 18-20, 2016 Dundee, Scotland Graeme Bilbe, R&D Director, will be speaking at this scientific conference celebrating the tenth anniversary of the Dundee Drug Discovery Unit.
  • ISNTD d3 2016 May 25-26, 2016 London, United Kingdom Eric Chatelain, Head of Drug Discovery, will present on drug discovery and development for Chagas disease.
  • DNDi Innovation & Access – Partners’ Meeting 2016 June 6-8, 2016 Rio de Janeiro, Brazil DNDi Latin America are organizing a series of events with conferences, discussions and meetings. International scientists, product developers, policy-makers, and civil society organizations, are invited to participate in the events in order to do the best science for the most neglected.
See all events